Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for...

Area of Science:

• Mycology
• Infectious Diseases
• Pharmacology

Background:

• Echinocandins are a class of antifungal drugs approved for treating candidal infections.
• In vitro studies indicate echinocandins exhibit reduced potency against Candida parapsilosis compared to other Candida species.
• Candida parapsilosis is a significant cause of candidiasis, particularly in healthcare settings.

Purpose of the Study:

• To report the first documented case of secondary multidrug resistance developing in a Candida strain during echinocandin therapy.
• To highlight the clinical implications of antifungal resistance in Candida parapsilosis infections.
• To emphasize the importance of monitoring treatment response in patients with candidiasis.

Main Methods:

• This study presents a clinical case report.
• Antifungal susceptibility testing was performed on serial isolates.
• Treatment regimens and patient outcomes were documented.

Main Results:

• A patient undergoing treatment for candidal infection developed a secondary multidrug-resistant Candida strain.
• The resistant strain exhibited resistance to both echinocandin and azole antifungal agents.
• This resistance emerged during the course of therapy.

Conclusions:

• The development of secondary multidrug resistance in Candida parapsilosis during therapy is a significant clinical concern.
• This case underscores the potential for Candida species to acquire resistance to multiple antifungal classes.
• Close monitoring and susceptibility testing are crucial for managing complex candidal infections.